Key Highlights

  • Tarsus Pharmaceuticals agreed to acquire privately held Alkeus Pharmaceuticals for approximately $450 million upfront, consisting of $270 million in cash and $180 million in Tarsus common stock, plus up to $350 million in potential milestone payments.
  • The deal brings Tarsus gildeuretinol, an investigational once-daily oral therapy for Stargardt disease, a rare inherited retinal disorder with no FDA-approved treatments that affects more than 36,000 people in the United States.
  • Tarsus separately announced an oversubscribed private placement expected to raise approximately $125 million in gross proceeds, with participation from existing Alkeus investors including TCGX, Bain Capital Life Sciences, and Wellington Management.
  • Topline data from the Phase 3 NORTHSTAR trial evaluating gildeuretinol are expected in the second half of 2029, with the trial designed in agreement with both the FDA and the European Medicines Agency.

Tarsus Expands Retina Pipeline With Alkeus Acquisition

Tarsus Pharmaceuticals (NASDAQ:TARS) announced a definitive agreement to acquire Alkeus Pharmaceuticals, a privately held biotechnology company developing gildeuretinol, an investigational oral therapy for Stargardt disease. Under the terms of the deal, Tarsus will pay approximately $450 million upfront, split between $270 million in cash and $180 million in Tarsus common stock priced at $61.38 per share, with an additional $350 million available through milestone payments tied to regulatory approval and first commercial sale, along with tiered royalties on future gildeuretinol sales. Stargardt disease is an inherited retinal condition that typically begins in childhood or adolescence and progressively damages central vision, with more than 36,000 people diagnosed in the United States and currently no FDA-approved therapies available. Gildeuretinol is designed to reduce the buildup of toxic vitamin A byproducts believed to drive the disease's underlying biology.

Clinical Program Shows Consistent Data Across More Than 400 Patients

The gildeuretinol clinical program has evaluated the therapy across all stages of Stargardt disease, drawing on more than seven years of tolerability data from over 400 treated patients. In the TEASE-1 study of 50 patients with advanced disease, gildeuretinol showed a 29.5% slower annualized growth rate of atrophic retinal lesions compared to an untreated arm, while a separate analysis found treated patients were 87% less likely to experience significant loss in low-light visual acuity. A second study, TEASE-2, evaluated 79 patients with reduced retinal sensitivity but without atrophic lesions at baseline. These findings informed the design of the ongoing Phase 3 NORTHSTAR trial, expected to enroll approximately 230 patients, with a primary endpoint measuring the rate of atrophic lesion growth over 24 months. The therapy has received Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from regulators.

Private Placement Draws Participation From Alkeus's Existing Investors

Alongside the acquisition, Tarsus announced an oversubscribed private placement expected to generate approximately $125 million in gross proceeds before fees. The financing includes participation from existing Alkeus investors such as TCGX, Bain Capital Life Sciences, and Wellington Management, alongside new and existing Tarsus investors including ADAR1 Capital Management, Sirenia Capital Management, RTW Investments, and Vestal Point Capital. Under the placement, Tarsus is selling roughly 2.1 million shares of common stock at $56.00 per share, along with pre-funded warrants to purchase an additional 133,625 shares. The financing is expected to close on August 7, 2026, with proceeds directed toward clinical development, commercial activities, and general corporate purposes. The Alkeus acquisition itself is expected to close later in 2026, pending antitrust clearance and other customary conditions, and is not contingent on the private placement's completion.

Conclusion

The Alkeus acquisition marks a further step in Tarsus's push to broaden its eye care pipeline beyond its approved Demodex blepharitis treatment, adding a late-stage retina program aimed at an inherited disease with no existing approved therapies. The accompanying private placement, bolstered by direct participation from Alkeus's own investor base, signals continuity of financial backing as the combined pipeline moves through clinical development. With Phase 3 data still several years away, the deal's ultimate value will likely hinge on whether gildeuretinol can replicate its early tolerability and efficacy signals in the larger NORTHSTAR trial population.